NDA 050609 · Hospira
Erythrocin
Erythromycin Lactobionate · Injection
Last checked: Nov 19, 2026Latest source record: Nov 18, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1986
Sep 24, 1986
Approved uses
1
Original approval plus efficacy supplements
Registered trials
5
1 Phase 3, 0 recruiting
FAERS reports
148
137 serious, 37 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 30, 2025.
INDICATIONS AND USAGE Erythrocin Lactobionate-IV (erythromycin lactobionate for injection, USP) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. Intravenous therapy should be replaced by oral administration at the appropriate time. Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci); Streptococcus pneumoniae (Diplococcus pneumoniae); Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information). Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci); Streptococcus pneumoniae (Diplococcus pneumoniae). Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes and Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: As an adjunct to antitoxin infections due to Corynebacterium diphtheriae to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae : Erythrocin Lactobionate-IV (erythromycin lactobionate for injection, USP) followed by erythromycin stearate or erythromycin base orally, as an alternative drug in...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 24, 1986 Original approval · Type 3 - New Dosage Form
2 products under this application
- ERYTHROCIN · ERYTHROMYCIN LACTOBIONATE EQ 500MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
- ERYTHROCIN · ERYTHROMYCIN LACTOBIONATE EQ 1GM BASE/VIAL · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Erythromycin Lactobionate" as an intervention, any sponsor and status, largest first.
- Intravenous Erythromycin Before Endoscopy in Patients With Variceal Bleeding: A Randomized, Double-Blind TrialPivotal-lookingCompleted
King Abdulaziz Medical CityGovernment (non-federal)
NCT01060267 · 102 participants · Start Jan 2007 · Primary completion May 2009
Drug: Erythromycin; Placebo · For: Variceal Bleeding
Sites: Riyadh, Saudi Arabia
- Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial PneumoniaPivotal-lookingTerminated
Melinta Therapeutics, Inc.Industry
NCT02605122 · 97 participants · Start Apr 2016 · Primary completion Mar 21, 2018
Drug: Solithromycin; Standard of Care · For: Community-acquired Bacterial Pneumonia
Sites: Little Rock, Arkansas; Los Angeles, California; Sacramento, California · 58 sites in all
Adil BharuchaAcademic, hospital or other
NCT02755064 · 30 participants · Start Jun 2010 · Primary completion Nov 2013
Drug: Erythromycin lactobionate; Placebo IV and 3 more · For: Diabetes Mellitus, Type 1
Sites: Rochester, Minnesota
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
NCT02633579 · 28 participants · Start Oct 2012 · Primary completion Aug 2014
Drug: erythromycin lactobionate; Atropine and 2 more · For: Healthy
Prof Dr Jan TackAcademic, hospital or other
NCT04066231 · 5 participants · Start Sep 7, 2019 · Primary completion Mar 10, 2020
Drug: Erythromycin Lactobionate · For: Gastric Motility
Sites: Leuven, Belgium
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- agranulocytosis19
- leukopenia19
- neutropenia16
- off label use14
- condition aggravated6
- diarrhoea6
- mixed liver injury6
- pneumonia6
- alanine aminotransferase increased5
- pyrexia5
- drug ineffective4
- hepatic function abnormal4
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2006 | 1 |
| 2007 | 6 |
| 2008 | 1 |
| 2009 | 11 |
| 2010 | 18 |
| 2011 | 18 |
| 2012 | 9 |
| 2013 | 5 |
| 2014 | 5 |
| 2015 | 1 |
| 2016 | 8 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 7 |
| 2022 | 19 |
| 2023 | 3 |
| 2024 | 7 |
| 2025 | 12 |
| 2026 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: a prospective evaluation and review of the literature.
Tschida SJ, Guay DR, Straka RJ, et al. · Pharmacotherapy 1996 · Clinical Trial, Randomized Controlled Trial
- Pharmacological modulation of human gastric volumes demonstrated noninvasively using SPECT imaging.
Liau SS, Camilleri M, Kim DY, et al. · Neurogastroenterol Motil 2001 · Clinical Trial, Randomized Controlled Trial
- Optimizing the erythromycin breath test for use in cancer patients.
Rivory LP, Slaviero K, Seale JP, et al. · Clin Cancer Res 2000 · Clinical Trial, Research Support, Non-U.S. Gov't
- Reduction of dental plaque deposition in humans by oolong tea extract.
Ooshima T, Minami T, Aono W, et al. · Caries Res 1994 · Clinical Trial, Randomized Controlled Trial
- Acute and chronic Legionnaires' disease and co-existent tuberculosis: a trial of erythromycin.
Hamedani P, Hafeez S, Ali J, et al. · Curr Med Res Opin 1989 · Clinical Trial
- Gallbladder contraction induced by intravenous erythromycin administration. Relation to body mass index.
Kakkos SK, Yarmenitis SD, Kalfarentzos F · Hepatogastroenterology 1996 · Clinical Trial, Randomized Controlled Trial
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.